Please login to the form below
Eliquis
This page shows the latest Eliquis news and features for those working in and with pharma, biotech and healthcare.
Post-merger Celgene to lead pharma growth
These show a 14% rise in revenues, driven upwards by a 19% surge in sales for its immunotherapy Opdivo and 28% growth for anticoagulant Eliquis.
Latest news
-
CHMP backs Lynparza in breast cancer, Dupixent in asthma
It was rejected by the CHMP a year ago. Ondexxya is intended for use in patients taking Pfizer/Bristol-Myers Squibb's Eliquis (apixaban), Bayer/Johnson &Johnson's Xarelto (rivaroxaban) as
-
BMS CEO tackles investor ‘frustrations’ on immuno-oncology
Overall, BMS reported an 8% increase in revenues to $5.7bn, with gains for Opdivo and Yervoy (up 18% to $382m) accompanied by a good performance from antiplatelet drug Eliquis (apixaban)
-
Pfizer CEO reckons rebates will disappear, and that’s a positive
Eliquis (apixaban), which rocketed 47% to $889m.
-
Pfizer’s flat sales focus investor attention on M&A
Once again, cancer drug Ibrance (palbociclib), anticoagulant Eliquis (apixaban) and Xeljanz (tofacitinib) for arthritis and other immunological indications led the charge, backed up by a solid advance for paediatric vaccine Prevnar
-
Bad news for Portola as CHMP considers Factor Xa drugs
Eliquis (apixaban), Bayer/Johnson &Johnson's Xarelto (rivaroxaban) and Daiichi Sankyo's Lixiana/Savaysa (edoxaban) - have thus far not been approved.
More from news
Approximately 14 fully matching, plus 71 partially matching documents found.
Latest Intelligence
-
The handover: Pfizer reshapes itself for a new era
Innovative health revenue increased 4% to $8.47bn, lifted by sales of blood thinner Eliquis and breast cancer drug Ibrance outside the US, among others.
-
The good, the bad and the ugly
This was largely thanks to Eliquis overtaking Bayer’s Xarelto as the leader in novel oral anticoagulants.
-
Modern anticoagulants threaten status quo
Apixaban. Bristol-Myers Squibb and Pfizer are developing apixaban (Eliquis), which is an oral, twice-daily, selective factor Xa inhibitor.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
PPD expands global product department with new therapeutic area heads
Puneet Mohan (left) comes to PPD from Bristol-Myers Squibb, where he most recently served as executive director of global clinical development and global clinical leader for Eliquis (apixaban).
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Account Director, Medical Education
-
Salary TBC
- Senior Account Manager- Pharma and Life Scienes
-
Competitive salary and benefits
-
Senior Medical Writer
-
Competitive salary and benefits
- Experienced / Senior Account Director - Publications - London
-
Up to £80, 000 plus great benefits
- Account Manager / Senior Account Manager - Healthcare Advertisin...
-
Excellent Remuneration
-
Director – Healthcare PR
-
Salary TBC
- NEW FREELANCE OPPORTUNITIES!!! LONDON and HOME WORKING!
-
EXCELLENT DAY RATES AVAILABLE
- Project Manager - Digital Healthcare - London
-
Excellent Remuneration Package
- Senior Account Director/ Associate Director- Pharma and Life Sci...
-
Competitive salary and benefits
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Account Director – London based Medical Communications Agency
-
Excellent Remuneration Package
- Freelance Medical Writer - Healthcare Advertising - London
-
Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day
- Senior / Principal Medical Writer - MedComms - Home Based / Vari...
-
Excellent Remuneration Packages
- Project Manager - Medical Communications – South Wales
-
Excellent Remuneration Package
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Editor – Medical Education Agency – Bucks
-
Salary TBC
-
Senior Medical Writer
-
Salary TBC
Subscribe to our email news alerts
PMHub
CSafe Global
CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...
Latest intelligence
- 04 A Healthy Ambience
- Creating a Lifeline to the New Digital User...
- 03 Health Services
- How Pharma Companies Can Survive the Patent Cliff Through Digital Innovation...
- From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
- How pharma is progressing their commitment in patient engagement...
Quick links
Infographics
